

Drug Utilization Review Board

Meeting Minutes

Thursday, November 14, 2019
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Katherine Smith, PharmD
Elizabeth Gargaro, MD
Eric Cannon, PharmD, FAMCP
Jennifer Brinton, MD
Judith Turner, DVM, PharmD

Kyle Kitchen, PharmD
Michelle Hoffman, MD
Neal Catalano, PharmD
Sharon Weinstein, MD
Susan Siegfried, MD

Board Members Excused:

Dept. of Health/Div. of Health Care Financing Staff Present:

Mohit Bhakta, PharmD
Andrea Rico, CPhT
Bryan Larson, PharmD

Jennifer Strohecker, PharmD
Ngan Huyhn, PharmD
Joe Busby, RPh, MBA

University of Utah Drug Regimen Review Center Staff Presenter:

Other Individuals Present:

Kelvin Yamashita, Sanofi Genzyme
Jason Murillo, Sanofi Genzyme
Deron Grothe, Teva

Jonny Sandoval, U of U Health Plans
Matthew Can, U of U Health Plans

Meeting conducted by: Katherine Smith, PharmD

1. **Welcome:** Katherine Smith opened the meeting, announced a quorum and reminded everyone to sign the rosters.
2. **Review and Approval of Choose an item Minutes:** Judith Turner made a motion to approve the meeting minutes as amended from October. Neal Catalano seconded the motion. All in favor, motion passed; Sharon Weinstein was not present for the vote.
3. **Housekeeping:**
 - a. **New DURB member:** Elizabeth Gargaro, MD provided a brief introduction of herself.
 - b. **Antipsychotic Use in Children:** Jennifer Strohecker discussed the upcoming policy changes effective January 2020.

- c. **Mandatory Three Month Supply:** Jennifer Strohecker reminded the board about this policy, explained the POS programming, and that this program has provided savings of over one million dollars in dispensing fees in six months.
 - d. **MME edit:** Jennifer Strohecker stated that the MME edit would be further decreased from 150 MME to 120 MME effective January 2020.
 - e. **Hemophilia Disease Management Program:** Jennifer Strohecker stated this disease management contract will cease effective January 2020. The disease management will be transitioned to the Accountable Care Organizations with designated case managers to assist their members and the Hemophilia Treatment Center provide care. The medication management will remain with Fee for Service.
- 4. **P&T Committee Update:** Bryan Larsen provided an updated on the September P&T Committee Meeting-Cytokine Modulators, and stated the conversation would be continued during the November P&T Committee meeting. The P&T Committee will also be discussing therapies used for Multiple Sclerosis.
- 5. **Antipsychotic Use in Children:**
 - a. **Information & Board Discussion:** Jennifer Strohecker presented on Antipsychotic Medications in Children, which is something that is a requirement of SUPPORT Act. There were several meetings held with a workgroup to design an approach that would address Antipsychotic Use in Children. This will be a dual approach for foster care children and non-foster care children, which will achieve the same message to all parties. Focus areas will include: 1) children under 6 years old on any antipsychotic within the last three months, 2) children and adolescents (19 years or younger) on more than one antipsychotic (90 days to look for overlap, greater than seven day overlap, prescriptions within the last three months), 3) children and adolescents (19 years or younger) on high doses of antipsychotics (as defined by FDA or TMAP, prescriptions within the last three months). Next steps will include: 1) establish all baseline data, including quality metric, 2) outreach group defined—all outreach done before January 2020 & UPOP will manage foster children, Medicaid Fee for Service will manage non-foster children, 3) Develop Antipsychotics in Children prior authorization form for DURB Review, 4) finalize outreach letter, 5) build and populate children/AP section on Medicaid Pharmacy website, 6) education for pharmacy staff regarding child psychiatry. Eric Cannon stated in the past Medicaid has had some issues with using diagnosis codes at the point of sale, pharmacies pick one diagnosis code and use it on every claim for every member that requires one. Jennifer Strohecker stated that this isn't something that can be prevented at this time, however, there will be surveillance on these diagnosis

codes which will include outreach to the pharmacy and the Utah Medicaid Peer to Peer program will be involved in this. Jennifer also stated that over half of the prescribing of these products is done by mid-level providers. Eric Cannon and Sharon Weinstein expressed concern about the mid-level providers prescribing these medications that are not mental health providers. Elizabeth Gargaro stated for the foster care population the vast majority of prescriptions are coming from either pediatricians or mid-level psychiatric providers who may or may not have child specific training. These medications are often very effective because they are powerful and are sedating. Utah Psychotropic Oversight Program identifies kids where a combination or escalation in meds that is concerning. UPOP is reaching out to the prescribers to try and help understand what is going on in that case and to provide education or support or other ideas like alternatives or safer medication, de-prescribing. Joe Busby and Ngan Huynh will be working on this project. Jennifer Strohecker presented the draft Antipsychotics in Children prior authorization form. The board discussed the criteria and proposed some changes. The final draft of the prior authorization will be updated for January 2020.

- b. **Board Action:** Sharon Weinstein motioned to approve the Antipsychotics in Children prior authorization form with accepted revisions, Eric Cannon seconded. Unanimous approval.

6. **Updated Hepatitis C Prior Authorization Form:**

- a. **Information:** Mohit Bhakta presented the Hepatitis C prior authorization form which has been updated to include the Mavyret label expansion to include eight week treatment duration for all HCV genotypes. Mohit explained the structure of the new prior authorization form.
- b. **Public Comment:** None
- c. **Board Discussion:** Michelle Hoffman inquired about utilization data and access to these medications. Jennifer Strohecker stated due to expansion the utilization of Hepatitis C medications has increased amongst the targeted adult Medicaid populations. Last year, there was extensive work on the PA form and removed the criteria that required an IV drug user be in some sort of treatment or remissions for that condition. Removing this criteria opened up access to these medications. There is higher utilization amongst FFS members than the members enrolled with our ACO partners. Joe stated the prior authorization approval rate is for FFS members is somewhere between 96-97%.
- d. **Board Action:** Eric Cannon motioned to approve the prior authorization form with accepted revisions, Sharon Weinstein seconded, unanimous approval.

7. **Makena Update:**

- a. **Information:** Mohit Bhakta discussed the recent FDA announcement regarding removing the approval for Makena. The recommendation is to continue using clinical guidelines for Makena until further notice from the FDA. Mohit inquired as to what the ACO partners are doing with Makena. Eric Cannon said they will

be doing the same thing. Currently, no change in practice.

8. **Bureau of Healthcare Policy & Authorization: Pharmacy Policy Updates January 2020**

- a. **MME High Dose Edit:** As previously stated the Utah Medicaid MME will be reduced from 150 MME to 120 MME effective January 2020.
- b. **Biologic/Biosimilar Interchangeability:** Mohit Bhakta presented an overview of the Biosimilar policy for Utah Medicaid. Utah Medicaid will continue to use the FDA “Purple Book” as a reference and unless otherwise limited through the prior authorization process, the State will not mandate interchange of biosimilars unless biologics are listed as interchangeable.

9. **Public Meeting Adjourned:** Eric Cannon motioned to close the meeting. Neal Catalano seconded the motion. Unanimous Approval.

10. **The next meeting scheduled for Thursday, January 09, 2020** Non-Controlled Drug of Abuse: Gabapentin.

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>